Log In
BCIQ
Print this Print this
 

PHT101 (PGC-C12E-Terlipressin)

  Manage Alerts
Collapse Summary General Information
Company PharmaIN Corp.
DescriptionAnalogue of vasopressin using Protected Graft Copolymer (PCG) delivery technology
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationCirrhosis
Indication DetailsTreat ascites due to all etiologies except cancer
Regulatory Designation U.S. - Orphan Drug (Treat ascites due to all etiologies except cancer)
PartnerBioVie Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/18/2016

0

0

0

Get a free BioCentury trial today